Searched for
DAIICHI SANKYO
NCLAT quashes Ligare Aviation's insolvency; loan from Religare Enterprises round-tripping of moneyThe National Company Law Appellate Tribunal has cancelled insolvency proceedings against Ligare Aviation. The tribunal found the National C...- After 50 hearings, court reserves judgement in Daiichi-Fortis caseThe Delhi High Court has reserved its judgment in a significant arbitration case. Japanese drug maker Daiichi Sankyo is seeking to enforce ...
- Fortis liability case: Delhi HC says blame can't be shifted to third partyAmid ongoing legal disputes, the Delhi High Court is probing Fortis Healthcare's oversight concerning the sale of shares belonging to the S...
- Chinese medicines bring relief to India’s cancer patientsIndia’s cancer treatment landscape is seeing a shift as lower-cost immunotherapy drugs developed in China and marketed through Indian partn...
- Tokyo Court to rule on Fortis arm IHH and Daiichi Sankyo disputeA significant legal battle between IHH Healthcare and Daiichi Sankyo is reaching its climax. The Tokyo District Court will announce its jud...
- IHH-Daiichi legal battle nears verdict on September 10A major legal battle between IHH Healthcare and Daiichi Sankyo is reaching its climax. IHH's subsidiary, NTK, is seeking JPY 200 billion in...
- Despite litigation, IHH says it is focused on key milestones for FortisMalaysia-based hospital operator IHH Healthcare has reached out to its largest shareholder Mitsui & Co. to help open communication with Jap...
- Sun Pharma: How a small Kolkata trader became a global buyout artistSun Pharma, led by Dilip Shanghvi, is poised for its largest overseas acquisition, a $12.5 billion deal for Organon & Co. This move continu...
- Fortis Open Offer: Daiichi Sankyo's 'misleading' statements continue to damage interests, says NTKIHH Healthcare's subsidiary, NTK, accuses Daiichi Sankyo of damaging its interests through misleading statements regarding the Fortis Healt...
- IHH Healthcare increases damages claim against Daiichi Sankyo to Rs 11,800 cr over Fortis acquisition disputeIHH Healthcare's indirect subsidiary, Northern TK Venture Pte Ltd, has significantly increased its damages claim against Daiichi Sankyo to ...
- IHH Healthcare claims 20 bn yen damages from Daiichi Sankyo for interference in Fortis Healthcare dealNorthern TK Venture Pte Ltd (NTK), a unit of Malaysia-based IHH Healthcare, has filed a lawsuit against Daiichi Sankyo in Tokyo District Co...
- Ranbaxy, Daiichi Sankyo to collaborate in Brazil to expand businessIn Brazil, Daiichi Sankyo has built up its market presence with innovative pharmaceuticals through Daiichi Sankyo Brazil.
- Ranbaxy, Daiichi Sankyo to leverage synergies in ThailandRanbaxy Laboratories and its Japanese parent Daiichi Sankyo to integrate their business operations in Thailand to maximise synergies.
- Daiichi Sankyo and Ranbaxy Launch hybrid business in VenezuelaDaiichi Sankyo & Ranbaxy announced that Daiichi Sankyo Venezuela would begin marketing Ranbaxy products in Venezuela as part of hybrid busi...
- Ranbaxy to sell Daiichi Sankyo product in MalaysiaDrug firm Ranbaxy Laboratories and Japan's Daiichi Sankyo today said Ranbaxy will market its parent company's products in Malaysia.
- Ranbaxy Laboratories to sell Daiichi Sankyo's products in ItalyRanbaxy Laboratories and its parent firm Daiichi Sankyo said they have entered into a partnership to distribute the Japanese firm's product...
- Ranbaxy, Daiichi Sankyo to expand business in MexicoThe two cos will launch Daiichi Sankyo's Olmesartan Medoxomil, used to treat high blood pressure, in Mexico before end of 2011.
- Daiichi to use Ranbaxy network to sell products in SingaporeRanbaxy and Daiichi Sankyo had signed a three-year plan to exploit synergies in operations to enhance their generic as well as branded busi...
- Ranbaxy transfers new drug discovery unit to Daiichi SankyoRanbaxy Laboratories on Friday said it has transferred its new drug discovery research unit (NDDR) to Daiichi Sankyo India Pharma.
- Daiichi Sankyo defers open offer to acquire Zenotech LabsDaiichi Sankyo has deferred the open offer to acquire 20% from public shareholders of Zenotech Labs as it is yet to get the approval from I...
Load More
